FDA to Host Public Meeting on Patient-Focused Drug Development for Rare Bleeding Disorders

Summary

The US Food and Drug Administration (FDA) will host a public meeting to discuss patient-focused drug development for hemophilia A, hemophilia B, von Willebrand disease, and other heritable bleeding disorders, as part of its efforts to improve treatment options for patients with these conditions.